Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic childhood: a report from Children's Oncology Group Study P9201

Allen R. Chauvenet,1,2 Paul L. Martin,3 Meenakshi Devidas,2,4 Stephen B. Linda,2,4 Beverly A. Bell,1 Kurtzberg,3 Jeanette Pullen,6 Mark J. Pettenati,7 Andrew J. Carroll,8 Jonathan J. Shuster,4 and Bruce Camitta

1 Department of Pediatrics, Wake Forest University Medical Center, Winston-Salem, NC; 2Children's Oncology Group, Arcadia, CA; 3Pediatric Blood and Marrow Transplant Division, Duke University Medical Center, Durham, NC; 4Department of Epidemiology and Health Policy Research, University of Florida, Gainesville; 5Pediatric Hematology/Oncology, Medical College of Georgia, Augusta; 6University of Mississippi Medical Center Children's Hospital, Jackson; 7Pediatrics/Medical Genetics, Wake Forest University Medical Center, Winston-Salem, NC; 8Department of Genetics, University of Alabama at Birmingham; and 9Pediatric Hematology/Oncology, Medical College of Wisconsin, Milwaukee

Corresponding author.

Received December 12, 2006; Accepted March 6, 2007.

Copyright © 2007 by The American Society of Hematology

Abstract

Pediatric Oncology Group (POG) protocol 9201 enrolled children with lesser-risk B-lineage lymphoblastic leukemia (ALL) defined by age (1-9), white blood cell count (WBC) less than 50 × 10^5 (50,000/µL), DNA findings of trisomies 4 and 10 (or DNA index > 1.16), and lack of overt nervous system (CNS) leukemia. After vincristine, prednisone, and asparaginase induction, 650 of 653 eligible patients attained remission (3 induction deaths) and received 6 courses of intravenous methotrexate (1 g/m²) with daily mercaptopurine. Weekly intramuscular methotrexate was added during maintenance; pulses of vincristine and prednisone were administered with periodic intrathecal chemotherapy. Treatment duration was 2.5 years. No alkylators, epipodophyllotoxins, anthracyclines, or radiation were given. The 6-year event-free survival (EFS) was 86.6% with overall survival (OS) of 97.2%. Patients with less than 5% marrow blasts on induction day 15 had superior EFS. A difference not reaching conventional statistical significance (P = .068) was noted for superior outcomes in patients with trisomies of chromosomes 4 and 10 versus those lacking double trisomies. Sex, ethr status, and WBC were not predictive. This indicates the great majority of children with lesser-risk B-lineage ALL are curable without agents with substantial late effects.

Introduction
B-lineage acute lymphoblastic leukemia (ALL) is the most common childhood malignancy in industrialized countries. Multiple different treatments have produced cures for a majority with ALL. A wide variety of prognostic factors have been used to separate patients into risk and higher risk. The Pediatric Oncology Group (POG) previously recognized patient “favorable” age and initial white blood cell count (WBC) by National Cancer Institute group criteria whose blasts have an elevated DNA index or trisomy of both chromosomes 4 and 10 in their leukemic cells to have an exceptionally good prognosis when treated with antimetabolite therapy, a finding supported by other studies. Because of the potential short- and long-term burden of therapy, POG 9201 was designed to extend this observation to a larger set of patients, attempting to clearly define a group of patients with an excellent prognosis even when treated with less treatment.

**Patients, materials, and methods**

**Patients**

The POG 9201 protocol opened as a limited institution pilot study in June 1992 and as a single-arm phase 3 group-wide study in November 1994. The study met accrual goals and patient enrollment in November 1999. Patients eligible for enrollment were diagnosed with ALL (confirmed by a central POG laboratory), aged 1 to 9 years, and had an initial WBC less than 50 $\times 10^9/L$ ($50,000/\mu L$). Evidence of trisomies 4 and 10 was required if cytogenetics were abr (informative); it was assumed that “normal” cytogenetic studies might reflect lack of cell division in the sample, and demonstration of a DNA index more than 1.16 was allowed as a surrogate marker; DNA index was determined by a POG reference laboratory and all cytogenetics were determined centrally or centrally reviewed by one of the authors (A.J.C.). Fluorescence in situ hybridization (FISH), to determine trisomies of chromosomes 4 and 10, was performed by another central POG reference laboratory (M.J.P.); these results were not used in determining eligibility for the study but are used in analysis of outcomes. Initial cerebrospinal fluid (CSF) either had no leukemic cells (CNS1) or, if blasts were present, had a total WBC less than 5 (CNS2). All grossly traumatic initial spinal taps in patients with circulating peripheral blasts were included in the CNS2 category even if no blasts were noted in the CSF itself provided the CSF WBC was less than 5. Patients with initial CNS3 status or testicular leukemia were excluded. During the years 1997 to 1998, when the POG had open studies for all patients with B-lineage ALL, this study accrued approximately (276/1374) of protocol registrations for patients older than 1 year. Informed consent for classification studies and registration on POG induction therapy was obtained from legal guardians of all patients prior to the initiation of treatment. A separate consent for POG 9201 was required at the end of induction. All informed consent documents were approved by the local institutional review boards of all institutions entering patients on this protocol, followed then-current POG guidelines, with the Declaration of Helsinki. This study (POG-9201) is registered with the National Cancer Institute (http://www.cancer.gov/clinicaltrials).

Between June 1992 and November 1999, a total of 658 patients were enrolled and initiated the POG 9400 classification study as described in this report. Two patients were biologic due to cytogenetic findings and 3 others were administratively ineligible due to improper
signing of informed consent. Three patients died prior to completing induction (2 from overwhelming sepsis present at the time of diagnosis and the third from unclear cause), and an additional patient developed biopsy-proven glomerulonephritis during induction and was not registered on treatment. Thus 653 of the 656 patients who were biologically eligible attained remission at the end of induction treatment, with the only failures being 3 induction deaths. Excluding patients for treatment on this protocol, the remaining 649 patients, all of whom attained remission, are included in this report. All data received by the statistical office and/or study coordinator as of April 29, 2004, were included in the analyses. Data through end of treatment or first event available for all patients with the exception of 4 who were removed from protocol therapy: 2 due to family relocations, 1 due to uncontrolled emesis, and 1 due to parental preference for care by a local physician. These patients were censored at that time point. Fifty-six percent of patients were white, 68.6% white, 17% Hispanic, 6.6% African American, and 7.8% other races. Median age at enrollment was 3.9 years (range: 1.0-9.9 years). Fifty-four patients had CNS2 involvement or a traumatic spinal tap (red blood cell count 10 or more) at diagnosis. Seventy-three percent of patients had a WBC less than $10^9$/L ($10^9$ cells/µL).

**Treatment plan**

Initial induction therapy for all patients included vincristine (1.5 mg/m² with 2.0 mg maximum dose) intravenously on days 1, 8, 15, and 22; prednisone 40 mg/m² per day in 3 divided doses, and L-asparaginase 6000 international units/m² intramuscularly on days 2, 5, 8, 12, 15, and 19. All patients received age-based intrathecal chemotherapy on days 1 and 15; patients with CNS2 status were treated identically to CNS1 patients except for also receiving IT chemotherapy on days 8 and 22 of induction. The initial protocol used triple intrathecal chemotherapy (methotrexate, hydrocortisone, and cytosine arabinoside). This was changed to methotrexate alone when therapeutic modifications were made to address CNS toxicity on companion protocols, although there was no indication of excess CNS toxicity in this study. The number of circulating blasts present on day 8 was recorded for the 368 patients who had circulating blasts present at the time of diagnosis. Percent residual blasts were determined by bone marrow morphology on days 15 and 29 of induction.

Consolidation therapy from weeks 5 to 25 included intravenous methotrexate 1 g/m² as a 24-hour infusion at weeks 7, 10, 13, 16, 19, and 22 with delayed leucovorin rescue along with oral 6-mercaptopurine (6MP), 50 mg/m² daily. Simultaneous intrathecal therapy was administered on weeks 10, 13, 16, 19, and 22. Pulses with 2 weekly doses of intravenous vincristine (1.5 mg/m² with 2.0 mg maximum dose) and 7 days of oral prednisone (40 mg/m² per day, in 3 divided doses, maximum daily dose 60 mg) were given from weeks 8 to 9 and 16 to 17.

Continuation therapy from weeks 25 to 130 included oral 6MP 75 mg/m² daily and IM methotrexate 20 mg/m² weekly. Pulses of vincristine and prednisone, as in consolidation, were given at weeks 41 to 42, 57 to 58, 73 to 74, 89 to 90, and 105 to 106. Intrathecal chemotherapy was given initially every 8 weeks through week 105, which was later modified (due to toxicity on companion protocols) to every 12 weeks to week 109. The original treatment schema is shown in Figure 1 above, some changes were made in intrathecal therapy for consistency with alterations in studies felt to have excess toxicity. Patients with initial CNS1 status thus received 14 to 20
treatments. There was no indication of a difference in outcome or toxicity related to the intrathecal prophylaxis schedule or drugs. Patients received Pneumocystis prophylaxis with trimethoprim/sulfamethoxazole, pentamidine, or dapsone from attainment of remission following the completion of therapy. A diagnostic lumbar puncture and bone marrow aspir with a physical examination and routine complete blood count (CBC) were required at the end of treatment (weeks 130-131). A routine testicular biopsy was not required. Diagnostic spine taps were planned at 4, 8, and 12 months off treatment while no off-treatment bone marrow aspirations were required in the absence of a clinical suspicion of relapse.

**Statistical analyses**

This was a single-arm nonrandomized study. Event-free survival (EFS) and overall survival (OS) were computed for all eligible patients on study. Time to an adverse event was defined as date of diagnosis until first relapse, second malignancy, or death from any cause. Patients experiencing an event were censored as of the date of last contact. The EFS and OS estimates were computed using the Kaplan-Meier method and standard errors of the estimates were determined according to Peto and Peto.

**Toxicity grading**

Toxicity was graded according to Common Toxicity Criteria (CTC) version 2.0: grade 3 indicating severe; grade 4, unacceptable or life-threatening toxicity; and grade 5, lethal toxicity. All toxicities were reviewed and scored by the primary study coordinator. Grade 1 and 2 toxicities (mild and moderate) were generally not considered significant, but all grade 2 or greater neurotoxicities were recorded.

**Results**

The 6-year EFS and OS were 86.6% ± 1.8% (± standard error) and 97.2% ± 0.87%, respectively (Figure 2). The highest risk for relapse was between 2 and 5 years from diagnosis.

Data were available from day-15 marrow aspirates on 571 patients (others did not have marrow aspirations or the quality was inadequate for interpretation). Patients with 5% or fewer blasts in day-15 marrows (n = 525) had superior EFS (87.6% ± 2.0%) compared with those (n = 46) with more than 5% blasts (76.1% ± 9.3%) with a P value of .010 as shown in Figure 3. This supports multiple prior observations regarding the prognostic value of early response, whether measured by peripheral blasts on day-8 or day-15 bone marrow aspiration. In this study, only 9 patients had more than 100 blasts/µL at day 8, too few to allow meaningful statistical analysis, although 2 of these 9 relapsed.

There were no statistically significant differences in EFS based upon sex, CNS status, eth WBC value (< 10 ×10^9/L versus 10-50 × 10^9/L [< 10 000 µ/L versus 10 000-50 000 µ/L]. A majority of patients on this study were CNS1 (595/649 or 91.7%). They had a 6-year EFS of 87.5% ± 1.8% compared with 76.8% ± 8.3% for those who were either CNS2 or had traumatic CSF at diagnosis (n = 54). With this small sample size, results favoring CNS1 patients did not reach standard statistical significance in EFS (P = .072). Separate analysis of the 28 patients with conven
Isolated testicular relapse (n = 7). Isolated testicular relapse was the initial event for 7 patients. Physical examination, and confirmed by biopsy. A single relapse was noted at the end of therapy between 3 to 8 months off treatment and 1 at 14 months off treatment. These patients were retreated with systemic chemotherapy and testicular radiation; all are alive and well in second remission, off treatment 16 to 54 months. The other patient refused conventional treatment and alternative medications for 6 months until he had a marrow relapse. This patient is currently in remission on treatment. Since all were late testicular relapses, they would be expected to have excellent salvage rates.

Isolated CNS relapse (n = 12). There were 12 patients with isolated CNS relapse as their initial event of whom 3 were diagnosed on treatment at weeks 84, 97, and 97. Routine end of treatment LPs identified 6 relapses. The other 3 were identified on routine LPs per protocol 5 to 13 months off treatment. One patient had headaches for a week prior to the end of treatment LP, while all others were asymptomatic at the time of CNS relapse.

There was one death from brain herniation shortly after an end of treatment CNS relapse (patient with headaches). All others had second systemic treatment including cranial or craniospinal radiation with one having a second CNS relapse. This patient is well 11 months following unrelated transplantation. All other patients are alive and well from 1 to 48 months off second treatment. This is in accord with anticipated salvage rates after late (> 18 months after diagnosis) isolated CNS relapse.

Combined CNS and testicular relapse (n = 1). A single patient had a CNS and testicular relapse 4 months off treatment and is in second remission 2 years off retreatment with chemotherapy and radiation.
Other extramedullary relapse sites (n = 4). Less common extramedullary relapse occurred in first was an extradural, lymphomatous mass (with flow cytometry identical to the original patient is more than a year off treatment in second remission. Another patient had a cort relapse 29 months off therapy with 5% marrow blasts marking like the original ALL and remission on chemotherapy 13 months after relapse. The third patient relapsed in a prea node 32 months off treatment and is in second remission after 3 months of treatment. Tl had an orbital relapse 7 months off therapy, received alternative treatments, had a marro died after a transplantation.

Extramedullary relapses with abnormal marrows (n = 3). There was one testicular relapse 2 n treatment with 7% marrow blasts. This patient was retreated with chemotherapy and tes radiation, remaining on treatment 23 months after relapse. Another patient had CNS dis routine LP 9 months off treatment and 8% marrow blasts. This patient had a marrow tra relapsed 21 months later, and had a second transplantation. He is free of disease 46 mon transplantation. The third patient had an ovarian relapse 22 months off treatment with 9 marrow and is off treatment, 44 months after relapse.

Bone marrow ± other sites (n = 50). There were 39 patients with isolated marrow relapse; 9 and 3 identified at end of treatment evaluation. Of these 12, 9 have died, 4 prior to and 5 transplantation; 3 survivors are 32 to 56 months after transplantation.

The 27 patients experiencing a posttreatment isolated marrow relapse did so 9 to 38 mon treatment. In this group, 11 had transplantations with 3 deaths, 1 in relapse, and 7 in remission 10 to 66 months after transplantation. There were 16 treated with intensive chemotherapy and 15 remission 10 to 66 months after relapse, while 1 is on treatment in third remission after a

Marrow relapse was combined with extramedullary relapse in 11 patients, 8 having CNS each CNS and testicular, testicular, and scalp relapses. One patient relapsed at week 61 a transplantation, while the others, relapsing 4 to 46 months off treatment remain alive 1 t after relapse, 2 after transplantations.

Relapses in patients previously removed from study (n = 2)

A patient off study for spinal myelopathy at week 23 received alternative chemotherapy & testicular relapse; he is 14 months off second treatment. Another patient transferred to a noncooperative group physician at week 69, received unknown treatment, and died after relapse. Both were counted as failing at relapse.

Toxicities

The therapy was generally well tolerated. While 560 (86.3%) of the patients had at least a grade 4 hematologic toxicity after induction, there were no episodes of fatal sepsis. The nonhematologic toxicity was elevated transaminases with 340 (52%) of patients having an episode of grade 3 or 4 toxicity. All of these were reversible and no patient was removed from therapy or had therapy withheld for an excessive period of time as a result.

Neurotoxicity
Acute neurotoxicity was noted in 57 patients (8.8%) during treatment. The great majority, although 2 patients developed major paralysis. The first had clinical findings compatible with Guillain-Barré syndrome shortly after bacterial sepsis. This patient developed spinal myelopathy and has stable paraplegia with a neurogenic bladder. The other patient developed acute quadriparesis at week 73 intrathecally as did 2 patients on other studies treated on the same day in the same institution; no additional intrathecal medications were given and the patient remains in remission. Extensive investigation failed to identify a cause (anonymous by request, oral personal communication, October 8, 1997).

Seizures occurred in 14 (2.2%) patients with 4 during induction, 2 having scans indicating CNS microthrombi, likely related to asparaginase. Of the remaining 10 seizures, 2 were attributed to infection: 1 with bacterial sepsis and 1 with erlichiosis in blood and CSF. Another was felt to be a febrile convulsion and one a new onset seizure disorder (focal seizure by electroencephalogram after most recent intrathecal medication with normal magnetic resonance imaging). The remaining 6 (one with neurofibromatosis) had seizures within 10 days of intrathecal medication with no other risk factors identified.

The relatively low seizure frequency may have been due to the fact that when intrathecal medications were given 3 weeks apart during consolidation, 5 of 6 were administered concurrently with intravenous methotrexate and followed by intravenous fluids and leucovorin rescue, unlike some other studies with a higher incidence of seizures in which more frequent intrathecal medications were administered, cranial radiation was given, and/or no intrathecal medications were immediately followed by leucovorin rescue. This also differs from the seizure frequency on companion POG studies that separated intravenous methotrexate and intrathecal chemotherapy and provided no leucovorin rescue after any intrathecal medications. A currently open Children’s Oncology Group study is examining this issue in greater detail through studies of neurologic outcomes of patients on differing studies.

Grade 2 or 3 headaches were reported in 5 patients, while 4 had transient motor weakness, ataxia, and/or visual complaints; all of these resolved.

There were 31 patients with motor or peripheral nerve toxicities related to vincristine, 6 of whom 3 were proven to have Charcot-Marie Tooth (CMT) disease. Of these patients, 18 had changes in vincristine dosing, and 1 patient (with CMT) received no vincristine after induction. All patients with CMT required physical therapy; 2 had long-lasting disabilities.

Deaths in remission

There were 2 deaths in remission, both due to varicella shortly after the week-73 to -74 pulse. Neither patient was neutropenic or lymphopenic at the time and both were treated within 24 hours of hospital admission. A detailed review of all 110 cases of varicella on this protocol found that more severe infections were seen in patients who received prednisone near the varicella infection.

Second malignancies
Myelodysplasia characterized by monosomy 7 developed in 2 patients; in neither case was the cytogenetic finding observed at original diagnosis. While this is unusual as a side effect of similar treatments, it has been reported. Both patients have had marrow transplantations and remission. It is noteworthy that one of these patients had a sibling develop ALL followed by monosomy 7 (Paul Bowman, MD, Cook Children’s Hospital, Fort Worth, TX, personal communication, November 5, 2003), which may imply a genetic link even though monosomy 7 was not identified at.

**Discussion**

It is clear that patients with high hyperdiploidy by virtue of trisomies of chromosomes such as 4, 10, and 18 potentially have a superior outcome. The United Kingdom group reported a 5-year EFS of 86% for low-risk females and a 5-year overall survival of 96% for all patients with trisomies 4 and 18. However, some studies have shown that lesser-risk children may actually have results similar to those in standard- and higher-risk groups if their therapy is not sufficiently intense. It is therefore critical to maintain sufficient intensity to preserve the excellent outcomes seen in this group of patients.

This study demonstrates that moderately-intensive antimetabolite-based chemotherapy than 90% long-term survival in young children with lesser-risk ALL, comprising approximately 20% of childhood cases of B-lineage ALL as noted above. It is noteworthy that none of these children received cranial radiation, anthracyclines or alkylating agents, dexamethasone, or topoisomerase inhibitors their initial treatment protocol. Results from Holland, the Nordic group, and several United States studies have demonstrated 5-year EFS of approximately 85% in their lowest-risk groups when cranial radiation was omitted, further supporting this approach to CNS prophylaxis.

A meta-analysis of worldwide trials including almost 3000 patients also showed equivalence of radiotherapy and long-term intrathecal therapy.

Intravenous methotrexate and intrathecal prophylaxis have been associated with long-term neurocognitive dysfunction, though the degree to which any one child is affected is uncertain. Encouraging studies, describing populations of adults, treated for ALL during childhood cranial radiation, have found that the likelihood of being employed, married, and insured with that of the general population. The relatively low seizure frequency in this study may be due to the fact that when intrathecal medications were given 3 weeks apart during consolidation, they were administered concurrently with intravenous methotrexate and thus were followed by intravenous fluids and leucovorin rescue as noted above.

Vincristine has been associated with long-term neuropathies, but the cumulative dose or low, as was the cumulative steroid dose. In this young population treated with prednisone dexamethasone, there were no reports of avascular necrosis recorded on the off-therapy submitted by participating institutions.

Thus it is likely that the great majority of the patients in this study will not only be long-term survivors but will do so with a minimum of significant late effects.

The issue of CNS2 status has been controversial with some noting this as an adverse prognostic feature and others finding these patients having outcomes identical to those of CNS1 patients.
This may relate to the fact that patients with initial traumatic CSF have also been noted to have inferior outcomes; they were thus grouped with CNS2 patients in this study. In these lesser-risk patients, with the addition of 2 intrathecal chemotherapy treatments during induction, there was no difference between the CNS1 patients and those in the CNS2 group, as also seen in the St. Jude Total Therapy XIIIIB, which used a similar strategy. This finding remained true when only those with CNS2 status as defined by Burger et al and Gajjar et al were considered. Whether the result in this defined patient group would have been obtained without this slight intensification of therapy is unknown. The number of CNS2 patients was small enough that a substantial difference in outcome would have been required to reach statistical significance.

Many previous studies have found differences in outcome based upon ethnic group, although studies have not confirmed this, and the issue when corrected for disease biology remains uncertain. Males have historically been reported to have an inferior prognosis, although recent studies focused on lesser-risk patients have found no significant differences related to sex. When sex was predictive of outcome in this study. There have been no deaths among the 44 African-American patients enrolled; the 6-year EFSs for males and females are 84.8% and 88.5%, respectively, with OSs of 96.4% and 98.2%. One assumes that this is due to the relative uniformity of this lesser-risk patient group, defined by age, WBC at diagnosis, favorable cytogenetics, and the absence of CNS3 disease. Thus, these host and disease characteristics are the more critical determinants of outcome.

A critical challenge remains, to identify patients at higher risk of relapse who might potentially benefit from more aggressive therapy. Even among this group of lesser-risk patients, greater than 10% of the patients had an event of some type by years 7 to 8. The patients without trisomies 4 and 10 had an EFS of about 80% and patients with more than 5% residual blasts on day-15 marrows had an EFS of about 75%. Patients with both of these unfavorable features (n = 6) had an EFS of 50%. Thus, an accurate assessment of blast cytogenetics and the use of early morphologic response to augment therapy may have improved the EFS and overall survival for the group as a whole, especially for those in the favorable group who are identified as having some higher-risk features. Whether the use of dexamethasone (instead of prednisone) or a delayed intensification phase would improve outcome is unknown. Some randomized studies, with excellent overall results, have demonstrated the superiority of dexamethasone, while other trials have not. A delayed intensification commonly improves outcome among standard-risk patients, but also adds anthracycline, an alkylating agent, and an increased risk of infection.

It should be noted that our study did not include patients with the TEL:AML translocation, which is now believed to also confer a generally favorable prognosis, except for slow molecular responders. These patients very rarely have hyperdiploidy and would largely represent a distinct group from those who were eligible for this study. Whether those with this translocation would have outcomes with this therapy is addressed by a subsequent study, POG 9904.

The patients in our study had an overall 7- to 8-year survival of more than 95%. This is in accord with smaller prior studies of patients selected for favorable host and disease characteristics. Further improvements in outcome, without increasing the burden of care for all, will rest on the identification of prognostic features, such as the presence of minimal residual disease, w...
so that selective intensification can be applied. Since significant late toxicities were uncommon, great care must be taken in regard to any reduction of therapy.\cite{26,27,48} However, it is clear that patients, identified in this study by the lack of trisomies of both chromosomes 4 and 10, slow initial response, or both, that has potential to benefit from further intensification of therapy. DNA microarrays, gene expression profiling, and other molecular measures of early response should provide more sensitive techniques for the identification of such slow responders.\cite{54-55} Conversely, that rapid disappearance of minimal residual disease, measured by techniques more sensitive than light microscopy, would be associated with an even better outcome than reported here, although selected for most favorable features by the techniques available in this study did not have significantly better than the entire population.

**Supplementary Material**

**[Supplemental Appendix]**

**Acknowledgments**

This work was supported by NIH grant U10CA98543. A.R.C. and Kathi Dale received support from NIH Grant U10CA30969 awarded to the Pediatric Oncology Group and COG Grant 98643. B. Georgia Cancer Coalition Distinguished Clinician. A complete listing of grant support for conducted by CCG and POG before initiation of the COG grant in 2003 is available online at [http://www.childrensoncologygroup.org/admin/grantinfo.htm](http://www.childrensoncologygroup.org/admin/grantinfo.htm).

The authors thank Mary Opel from the COG Statistical Office in Gainesville, FL, whose efforts made possible the accurate collection of data for all patients. We also thank Kathi Dale whose help in organizing data for the first author was invaluable; Mike Nash of St Jude Children’s Hosptial determination of DNA index on all samples; and Dr Michael Borowitz of Johns Hopkins confirmation of the lineage in all cases. Dr Naomi Winick made numerous suggestions that greatly improved the paper. Finally, we greatly appreciate the CRAs, RNs, PNPs, and MDs of the institutions participating in this study for timely data submission and rapid responses to the study coordinators. The authors also appreciate the valuable assistance of Donna Correia and Roxanne Hernandez in the COG Publications Office.

**Footnotes**

An Inside *Blood* analysis of this article appears at the front of this issue.

The online version of this article contains a data supplement.

Presented in abstract form at the American Society of Pediatric Hematology/Oncology meeting, Wash 16, 2005.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and sol fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

**Authorship**

Contribution: A.R.C. designed the study, reviewed all patient data in detail, and was the
of the paper; P.L.M. was the secondary coordinator, answered queries when A.R.C. was absent, contributed to the design, and reviewed all amendments; S.B.L. and M.D. performed the analyses; B.A.B. coordinated a companion protocol and worked closely with the first author regarding all the amendments and review of outcome data; J.K. coordinated a companion protocol closely with the first author regarding all amendments and overall study design; J.P. coordinated POG 9400 classification protocol to assure assignment of patients to the correct treatment; reviewed questions regarding this study during the time of patient accrual; M.J.P. performed FISH analysis on all study patients, coordinated submission of results to the statistical office, a karyotype review; A.J.C. performed karyotypes on large numbers of patients and reviewed results for each patient entered in the study; J.J.S. designed statistical aspects of the study; B.C., working with the first author on this matter, contributed to the paper.

A complete list of Children’s Oncology Group Study P9201 participating institutions is provided in Document S1, available on the Blood website; see the Supplemental Appendix link at the online article.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Allen R. Chauvenet, Children’s Oncology Group, 440 E Huntington Dr, Arcadia, CA 91006; e-mail: achauvenet@triad.rr.com.

References


7. Schrappe M, Reiter A, Zimmerman M, et al. Long-term results of four consecutive trials...


**Figures and Tables**
**POG 9201 TREATMENT SCHEMA**

**INDUCTION (weeks 1-4)**

<table>
<thead>
<tr>
<th>Day</th>
<th>1</th>
<th>8</th>
<th>15</th>
<th>22</th>
<th>29</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRED</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VCR</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>L-ASP</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>TIT</td>
<td>X</td>
<td>X*</td>
<td>X*</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>EMA</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

*X* = For patients with <5 WBC/l and blasts in CSF at diagnosis

**CONSOLIDATION (weeks 5-24)**

**Weeks 7, 10, 13, 16, 19, 22**

<table>
<thead>
<tr>
<th>Day</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTX</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>LCV</td>
<td></td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

MTX = Methotrexate 200 mg/m² IV push followed by 600 mg/m² over 24 hours

LCV = Leucovorin 10 mg/m² P.O. or IV q 6 hours x 5 doses beginning 42 hours after start of MTX infusion

**Week** | 5 | 7 | 9 | 10 | 13 | 16 | 17 | 19 | 22 | 24 | 6-MP | X | X | X | X |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TIT</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

FRED = For patients with <5 WBC/l and blasts in CSF at diagnosis

**MAINTENANCE (weeks 25-130)**

**Weeks** | 25 | 33 | 41 | 49 | 57 | 66 | 73 | 81 | 99 | 97 | 105 |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FRED</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VCR</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

FRED = 7 consecutive days starting indicated week

VCR = 2 doses, 8 days apart starting indicated week

**Weeks** | 25 |     | 130 |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>6-MP</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IM MTX</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

6-MP = 75 mg/m²/day x 7 days a week

IM MTX = 20 mg/m² weekly (1/2 dose day of IT meds)

POG 9201 treatment schema.
POG 9201 event-free and overall survival.
Figure 3

POG 9201 EFS by day 15 marrow status.

POG 9201 EFS by day-15 marrow status.
POG 9201: EFS by +4/+10 Status

$P = .068$

- +4/+10 not present (n=94)
- +4/+10 present (n=555)

POG 9201 EFS by trisomy +4/+10 status.